Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line-IPO43

被引:4
作者
Silva, Fernanda [1 ]
Coelho, Filipa [1 ,2 ]
Peixoto, Ana [3 ]
Pinto, Pedro [4 ]
Martins, Carmo [2 ]
Frombach, Ann-Sophie [5 ,6 ]
Santo, Vitor E. [5 ,6 ]
Brito, Catarina [5 ,6 ]
Guimaraes, Antonio [7 ]
Felix, Ana [1 ,8 ]
机构
[1] Univ NOVA Lisboa, Chron Dis Res Ctr, NOVA Med Sch, CEDOC FCM UNL,NMS, P-1169056 Lisbon, Portugal
[2] Portuguese Inst Oncol Francisco Gentil Lisbon IPO, Mol Pathobiol Res Unit, P-1099023 Lisbon, Portugal
[3] Portuguese Oncol Inst Porto, Dept Genet, Porto, Portugal
[4] Portuguese Oncol Inst Porto, IPO Res Ctr, Porto, Portugal
[5] Inst Biol Expt & Tecnol PT, IBET, P-2781901 Oeiras, Portugal
[6] Univ NOVA Lisboa, Inst Tecnol Quim & Biol Antonio Xavier, P-2780157 Oeiras, Portugal
[7] IPOLFG, Med Oncol Serv, P-1099023 Lisbon, Portugal
[8] IPOLFG, Dept Pathol, P-1099023 Lisbon, Portugal
关键词
Ovarian cancer; Cell lines; Chemoresistance; 3D models; COMPARATIVE GENOMIC HYBRIDIZATION; CANCER; P53; STRATEGIES; CISPLATIN; MARKERS;
D O I
10.1186/s12935-022-02600-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Epithelial ovarian cancer (EOC) is an aggressive and lethal malignancy and novel EOC cell lines with detailed characterization are needed, to provide researchers with diverse helpful resources to study EOC biological processes and cancer experimental therapies. Methods The IPO43 cell line was established from the ascitic fluid of a patient with a diagnosis of high-grade serous carcinoma (HGSC) of the ovary, previously treated with chemotherapy. Cell immortalization was achieved in 2D cell culture and growth obtained in 2D and 3D cell cultures. The characterization of immortalized cells was done by immunocytochemistry, flow cytometry, cell proliferation, chromosomal Comparative Genomic Hybridization (cCGH), STR profile and Next Generation Sequencing (NGS). Results Characterization studies confirmed that IPO43 cell line is of EOC origin and maintains morphological and molecular features of the primary tumor. cCGH analysis showed a complex profile with gains and losses of specific DNA regions in both primary ascitic fluid and cell line IPO43. The cell line was successfully grown in a 3D system which allows its future application in more complex assays than those performed in 2D models. IPO43 cell line is resistant to standard drug treatment in vitro. Conclusions IPO43 is available for public research and we hope it can contribute to enrich the in vitro models addressing EOC heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities.
引用
收藏
页数:17
相关论文
共 34 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]  
Aquilina G, 2000, CLIN CANCER RES, V6, P671
[3]   Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes [J].
Beaufort, Corine M. ;
Helmijr, Jean C. A. ;
Piskorz, Anna M. ;
Hoogstraat, Marlous ;
Ruigrok-Ritstier, Kirsten ;
Besselink, Nicolle ;
Murtaza, Muhammed ;
van IJcken, Wilfred F. J. ;
Heine, Anouk A. J. ;
Smid, Marcel ;
Koudijs, Marco J. ;
Brenton, James D. ;
Berns, Els M. J. J. ;
Helleman, Jozien .
PLOS ONE, 2014, 9 (09)
[4]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[5]   DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset [J].
Berg, Marianne ;
Danielsen, Stine A. ;
Ahlquist, Terje ;
Merok, Marianne A. ;
Agesen, Trude H. ;
Vatn, Morten H. ;
Mala, Tom ;
Sjo, Ole H. ;
Bakka, Arne ;
Moberg, Ingvild ;
Fetveit, Torunn ;
Mathisen, Oystein ;
Husby, Anders ;
Sandvik, Oddvar ;
Nesbakken, Arild ;
Thiis-Evensen, Espen ;
Lothe, Ragnhild A. .
PLOS ONE, 2010, 5 (11)
[6]   Association of breast cancer outcome with status of p53 and MDM2 SNP309 [J].
Boersma, Brenda J. ;
Howe, Tiffany M. ;
Goodman, Julie E. ;
Yfantis, Harry G. ;
Lee, Dong H. ;
Chanock, Stephen J. ;
Ambs, Stefan .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (13) :911-919
[7]   Common variants at 19p13 are associated with susceptibility to ovarian cancer [J].
Bolton, Kelly L. ;
Tyrer, Jonathan ;
Song, Honglin ;
Ramus, Susan J. ;
Notaridou, Maria ;
Jones, Chris ;
Sher, Tanya ;
Gentry-Maharaj, Aleksandra ;
Wozniak, Eva ;
Tsai, Ya-Yu ;
Weidhaas, Joanne ;
Paik, Daniel ;
Van den Berg, David J. ;
Stram, Daniel O. ;
Pearce, Celeste Leigh ;
Wu, Anna H. ;
Brewster, Wendy ;
Anton-Culver, Hoda ;
Ziogas, Argyrios ;
Narod, Steven A. ;
Levine, Douglas A. ;
Kaye, Stanley B. ;
Brown, Robert ;
Paul, Jim ;
Flanagan, James ;
Sieh, Weiva ;
McGuire, Valerie ;
Whittemore, Alice S. ;
Campbell, Ian ;
Gore, Martin E. ;
Lissowska, Jolanta ;
Yang, Hanna P. ;
Medrek, Krzysztof ;
Gronwald, Jacek ;
Lubinski, Jan ;
Jakubowska, Anna ;
Le, Nhu D. ;
Cook, Linda S. ;
Kelemen, Linda E. ;
Brook-Wilson, Angela ;
Massuger, Leon F. A. G. ;
Kiemeney, Lambertus A. ;
Aben, Katja K. H. ;
van Altena, Anne M. ;
Houlston, Richard ;
Tomlinson, Ian ;
Palmieri, Rachel T. ;
Moorman, Patricia G. ;
Schildkraut, Joellen ;
Iversen, Edwin S. .
NATURE GENETICS, 2010, 42 (10) :880-+
[8]   Global estimates of cancer prevalence for 27 sites in the adult population in 2008 [J].
Bray, Freddie ;
Ren, Jian-Song ;
Masuyer, Eric ;
Ferlay, Jacques .
INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (05) :1133-1145
[9]   The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth [J].
Cadwell, C ;
Zambetti, GP .
GENE, 2001, 277 (1-2) :15-30
[10]  
Cory G., 2011, METHODS MOL BIOL